Search Results

You are looking at 1 - 10 of 37 items :

  • "androgenetic alopecia" x
Clear All

. [Regulation of human hair growth by cosmetics - facts and myths]. Dermatol Estet 2007; 6(53):367-377. 5. Blume-Peytavi U, Blumeyer A, Tosti A Finner A, Marmol V, Trakatelli M. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol 2010; 164:5-15. 6. Aburjai T, Natsheh F. Plants used in cosmetics. Phytother Res 2003; 17(9):987-1000. 7. Messenger A. Male Androgenetic Alopecia. In: Blume-Peytavi U, Tosti A, Whiting DA, Trűeb RM (eds). Hair Growth and Disorders. Berlin, Springer-Verlag, 2008:166-168. 8. Park WS, Lee CH, Lee

Horm Mol Biol Clin Invest 2010;1(2):95–102 2009 by Walter de Gruyter • Berlin • New York. DOI 10.1515/HMBCI.2010.010 2010/16 Article in press - uncorrected proof The influence of low dose finasteride, a type II 5a-reductase inhibitor, on circulating neuroactive steroids Michaela Dušková*, Martin Hill and Luboslav Stárka Institute of Endocrinology, CZ 11694 Prague 1, Czech Republic Abstract Background: Finasteride is a 5a-reductase inhibitor that has received clinical approval for the treatment of human benign prostatic hyperplasia and androgenetic alopecia


Introduction. Capillaroscopy is a non-invasive imaging method that allows cutaneous microcirculation to be analyzed. During the last decades, a diagnostic and prognostic potential of nailfold capillaroscopy (NVC) has been gaining increasing appreciation. The main indications include Raynaud phenomenon and scleroderma spectrum diseases, however the usefulness of this technique is also suggested in a variety of non-rheumatic diseases.

Aim. To assess capillaroscopic patterns in systemic scleroderma (SSc), psoriasis (PV), psoriatic arthritis (PsA), alopecia areata (AA) and androgenetic alopecia. To evaluate serum levels of several endothelial and angiogenic markers, and their relation to capillaroscopic pattern.

Material and methods. There were evaluated 295 patients with systemic scleroderma (SSc), psoriasis (PV), psoriatic arthritis (PsA), alopecia areata (AA) and androgenetic alopecia, as well as age- and sex-matched controls, were examined. In each subject, NVC was performed and serum concentration levels of several angiogenic markers.

Results. In SSc three NVC patterns: early, active and late were distinguished. Angiopoietin-2 concentrations were higher and andothelial microparticles were lower in patients with late NVC pattern. We found several differences between the NVC pattern in PV and PsA. No correlations between NVC pattern and serum levels of angiogenic markers were revealed. In AA, we distinguished both normal and abnormal NVC patterns, although the normal patterns were more frequent. Branching capillaries and features of neoformation were often present in patients with the abnormal pattern. In androgenetic alopecia, the normal NVC pattern was most frequently present, however, we found several statistically significant capillarosopic alterations, like branching capillaries, features of neoformation and altered distribution of capillaries.

Discussion and Conclusions. Serum levels of Ang-2 and EMPs may reflect capillary damage in SSc. NVC pattern varies between PV and PsA patients. The presence of abnormal NVC patterns in alopecia patients might show the role of disturbances in microcirculation in the diseases. Further studies are required to confirm the hypothesis.

the treatment of androgenetic alopecia: a randomized comparative trial, Skinmed. 13 (2015) 15–21. 10. M. Y. Dhariwala and P. Ravikumar, An overview of herbal alternatives in androgenetic alopecia, J. Cosmet. Dermatol. (2019); 11. B. Y. Choi, Hair-growth potential of ginseng and its major metabolites: A review on its molecular mechanisms, Int. J. Mol. Sci. 19 (2018) E2703; 12. H. J. Ryu, M. G. Yoo and S. W. Son, The efficacy of 3% minoxidil vs. combined 3% minoxidil and Korean red ginseng

zykli- scher Einnahme immer wieder in der Einnahmepause anlaufende An- drogensynthese im Ovar reduziert oder ganz vermieden. Literatur: 1. Jamin C: Androgenetic alopecia. Ann Dermatol Venerol 129 (2002) 801– 803. 2. Paterson H, Clifton J, Miller D, Ashton J, Harrison-Woolrych M: Hair loss with use of the levonorgestrel intrauterine device. Contraception 76 (2007) 306–209. 3. Raudrant D, Rabe T: Progestogens with antiandrogenic properties. Drugs 6 (2003) 463–492. 4. Vexiau P, Chaspoux C, Boudou P, Fiet J, Jouanique C, Hardy N, et al.: Ef- fects of minoxidil 2% vs

163-e171. 6. Yoo HG, Kim JS, Lee SR, Pyo HK, Moon HI, Lee JH, Kwon OS, Chung JH, Kim KH, Eun HC, Cho KH. Perifollicular fibrosis: pathogenetic role in androgenetic alopecia. Biol Pharm Bull 2006; 29:1246-1250. 7. Bhaumik S, Jyothi MD, Khar A. Differential modulation of nitric oxide production by curcumin in host macrophages and NK cells. FEBS Lett 2000; 483:78-82. 8. Paul PHB, Po-Ming H, Hui C, Dominic Chan TW, Bo-Mu W, Thomas CWM, Chun-Tao C. Sesquiterpenes lactone from Elephatopus scaber. Phytochemistry 1997; 44: 113-116. 9. De Silva LB, Hearth WHMW, Jennings RC

M, Tagami M. Functional analysis of the stratum corneum of scalp skin: studies in patients with alopecia areata and androgenetic alopecia. Arch Dermatol Res. 292: 605-611, 2000. Bhat YJ, Gupta V, Kudyar RP. Cutaneous manifestations of diabetes mellitus. Int J Diab Ctries December 26(4): 152-155, 2006. Diris N, Colomb M, Leymarie F et al. Dermatoses non infectieuses au cours du diabète sucré. Etude prospective de 308 malades. Ann Dermatol Venereol 130: 1009-14, 2003. Nishikawa T, Edelstein D, Du XL et al. Normalizing mitochondrial superoxid production

bioavailable testosterone. Exp Clin Endocrinol Diabetes 2006 ; 114 : 182 –7. 14. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977 ; 97 : 247 –54. 15. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 ; 28 : 412 –9. 16. Babson AL, Olson DR, Palmieri T, Ross AF, Becker DM, Mulqueen PJ. The IMMULITE assay tube: a new approach

Introduction 5α-Reductase inhibitors (5α-RIs) finasteride and dutasteride and α-adrenergic receptor blockers (ARB), such as tamsulosin, are widely used treatments of lower urinary tract symptoms (LUTS), secondary to benign prostatic hyperplasia (BPH) [ 1 ], [ 2 ]. 5α-RIs therapy with finasteride is also widely used for treatment of male pattern hair loss (MPHL) commonly known as androgenetic alopecia (AGA) [ 3 ], [ 4 ]. However, among the main concerns of 5α-reductase inhibitors therapy is the potential serious adverse sexual side effects [ 1 ], [ 5 ], [ 6 ], [ 7

Introduction 5α-Reductase inhibitors (5α-RIs) therapy with finasteride or dutasteride and α1-adrenergic receptor blockers such as tamsulosin are widely used for treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) [1, 2]. 5α-RIs therapy with finasteride is also widely used for treatment of male pattern hair loss (MPHL), commonly known as androgenetic alopecia (AGA) [3, 4]. However, one of the main concerns with 5α-RIs therapy is the serious adverse effects on sexual function [1, 5–16]. Considerable controversy exists